170 related articles for article (PubMed ID: 9788557)
1. Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
Essioux L; Girodet C; Sinilnikova O; Pagès S; Eisinger F; de Résende S; Maugard C; Lanoë D; Longy M; Bignon YJ; Sobol H; Bonaïti-Pellié C; Stoppa-Lyonnet D
Am J Med Genet; 1998 Sep; 79(3):175-83. PubMed ID: 9788557
[TBL] [Abstract][Full Text] [Related]
2. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
3. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
4. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Tonin PN; Mes-Masson AM; Futreal PA; Morgan K; Mahon M; Foulkes WD; Cole DE; Provencher D; Ghadirian P; Narod SA
Am J Hum Genet; 1998 Nov; 63(5):1341-51. PubMed ID: 9792861
[TBL] [Abstract][Full Text] [Related]
5. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Serova OM; Mazoyer S; Puget N; Dubois V; Tonin P; Shugart YY; Goldgar D; Narod SA; Lynch HT; Lenoir GM
Am J Hum Genet; 1997 Mar; 60(3):486-95. PubMed ID: 9042907
[TBL] [Abstract][Full Text] [Related]
6. Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Mavaddat N; Rebbeck TR; Lakhani SR; Easton DF; Antoniou AC
Breast Cancer Res; 2010; 12(3):R28. PubMed ID: 20482762
[TBL] [Abstract][Full Text] [Related]
7. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
8. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Rebbeck TR; Couch FJ; Kant J; Calzone K; DeShano M; Peng Y; Chen K; Garber JE; Weber BL
Am J Hum Genet; 1996 Sep; 59(3):547-53. PubMed ID: 8751855
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
Sarantaus L; Auranen A; Nevanlinna H
Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
[TBL] [Abstract][Full Text] [Related]
12. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
[TBL] [Abstract][Full Text] [Related]
13. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
[TBL] [Abstract][Full Text] [Related]
14. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Ligtenberg MJ; Hogervorst FB; Willems HW; Arts PJ; Brink G; Hageman S; Bosgoed EA; Van der Looij E; Rookus MA; Devilee P; Vos EM; Wigbout G; Struycken PM; Menko FH; Rutgers EJ; Hoefsloot EH; Mariman EC; Brunner HG; Van 't Veer LJ
Br J Cancer; 1999 Mar; 79(9-10):1475-8. PubMed ID: 10188893
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
[TBL] [Abstract][Full Text] [Related]
17. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
18. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
Cui J; Antoniou AC; Dite GS; Southey MC; Venter DJ; Easton DF; Giles GG; McCredie MR; Hopper JL
Am J Hum Genet; 2001 Feb; 68(2):420-31. PubMed ID: 11133358
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
20. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]